Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topisistat tablets in gout with hyperuricemia (dose–response, randomized double-blind active-controlled Phase II study)
CTR20252295Phase 2Active
- Sponsor
- Sinopharm Rongsheng Pharmaceutical
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of topisistat in gout and hyperuricemia (2 arms), sponsored by Sinopharm Rongsheng Pharmaceutical. Primary endpoint: Serum uric acid target attainment at Week 12. Started Aug 2025; status: active.
02
Drugs
topisistat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20252295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252295.